Targeted immune modulators for rheumatoid arthritis: effectiveness and value : evidence report
- Collection:
- Health Policy and Services Research
- Contributor(s):
- Institute for Clinical and Economic Review, issuing body. New England Comparative Effectiveness Public Advisory Council, issuing body.
- Publication:
- [Boston, Massachusetts] : Institute for Clinical and Economic Review, April 7, 2017
- Language(s):
- English
- Format:
- Text
- Subject(s):
- Arthritis, Rheumatoid -- drug therapy Arthritis, Rheumatoid -- immunology Immunologic Factors -- therapeutic use Abatacept -- therapeutic use Adalimumab -- therapeutic use Antirheumatic Agents -- adverse effects Antirheumatic Agents -- therapeutic use Certolizumab Pegol -- therapeutic use Cost-Benefit Analysis Drug Therapy, Combination Etanercept -- therapeutic use Immunologic Factors -- adverse effects Infliximab -- therapeutic use Interleukin-6 -- antagonists & inhibitors Janus Kinase Inhibitors -- therapeutic use Randomized Controlled Trials as Topic Rituximab -- therapeutic use Tumor Necrosis Factors -- antagonists & inhibitors Humans United States
- Genre(s):
- Technical Report
- Copyright:
- Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. (More information)
- Extent:
- 1 online resource (1 PDF file (vii, ES32, 529 pages))
- Illustrations:
- Illustrations
- NLM Unique ID:
- 101723892 (See catalog record)
- Permanent Link:
- http://resource.nlm.nih.gov/101723892